Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas

Andrea Horváth, Csanad G. Varallyay, Daniel Schwartz, Gerda B. Toth, Joao P. Netto, Ramon Barajas, Péter Várallyay, László Szidonya, Jenny Firkins, Emily Youngers, Rongwei Fu, Prakash Ambady, P. Bogner, Edward A. Neuwelt

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Delayed ferumoxytol enhancement on T1-weighted images appears visually similar to gadoteridol enhancement. The purpose of this study was to quantitatively compare ferumoxytol T1 enhancement to gadoteridol enhancement with an objective, semi-automated method. Methods: 206 sets of post-gadoteridol and 24 h post-ferumoxytol T1-weighted scans from 58 high grade glioma patients were analyzed (9 pre-chemoradiation, 111 < 90 days post-chemoradiation, 21 > 90 days post-chemoradiation, 65 post-bevacizumab scans). Enhancement volumes and signal intensities normalized to normal appearing tissue proximal to enhancement were calculated with a semi-automated method. Enhancement cube root volumes (D) and signal intensities (SI) were compared between the 2 contrast agents, and relative difference of D and SI were compared in different treatment groups with multivariate analysis. Within patient differences in D and SI before and after treatment with bevacizumab or steroid were assessed in 26 patients in each treatment group. Results: When compared to gadoteridol, ferumoxytol D was 13.83% smaller and SI was 7.24% lower (P < 0.0001). The relative differences in D and SI between the 2 contrast agents were not significantly different between treatment groups (P > 0.05). Relative difference in D and SI did not change significantly in response to bevacizumab (P = 0.5234 and P = 0.2442, respectively) or to steroid (P = 0.3774, P = 0.0741) in the within patient comparison. Conclusion: The correlation between the 2 contrast agents’ enhancement size and signal intensity and their similar behavior in response to therapy suggest that ferumoxytol can be used for revealing enhancement in high grade glioma patients. Magn Reson Med 80:224–230, 2018.

Original languageEnglish
Pages (from-to)224-230
Number of pages7
JournalMagnetic Resonance in Medicine
Volume80
Issue number1
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Ferrosoferric Oxide
Glioma
Contrast Media
Steroids
Therapeutics
Multivariate Analysis
gadoteridol
Bevacizumab

Keywords

  • alternative contrast agent
  • delayed enhancement
  • ferumoxytol
  • gadoteridol
  • glioblastoma
  • USPIO

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Horváth, A., Varallyay, C. G., Schwartz, D., Toth, G. B., Netto, J. P., Barajas, R., ... Neuwelt, E. A. (2018). Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas. Magnetic Resonance in Medicine, 80(1), 224-230. https://doi.org/10.1002/mrm.27028

Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas. / Horváth, Andrea; Varallyay, Csanad G.; Schwartz, Daniel; Toth, Gerda B.; Netto, Joao P.; Barajas, Ramon; Várallyay, Péter; Szidonya, László; Firkins, Jenny; Youngers, Emily; Fu, Rongwei; Ambady, Prakash; Bogner, P.; Neuwelt, Edward A.

In: Magnetic Resonance in Medicine, Vol. 80, No. 1, 01.07.2018, p. 224-230.

Research output: Contribution to journalArticle

Horváth, A, Varallyay, CG, Schwartz, D, Toth, GB, Netto, JP, Barajas, R, Várallyay, P, Szidonya, L, Firkins, J, Youngers, E, Fu, R, Ambady, P, Bogner, P & Neuwelt, EA 2018, 'Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas', Magnetic Resonance in Medicine, vol. 80, no. 1, pp. 224-230. https://doi.org/10.1002/mrm.27028
Horváth, Andrea ; Varallyay, Csanad G. ; Schwartz, Daniel ; Toth, Gerda B. ; Netto, Joao P. ; Barajas, Ramon ; Várallyay, Péter ; Szidonya, László ; Firkins, Jenny ; Youngers, Emily ; Fu, Rongwei ; Ambady, Prakash ; Bogner, P. ; Neuwelt, Edward A. / Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas. In: Magnetic Resonance in Medicine. 2018 ; Vol. 80, No. 1. pp. 224-230.
@article{75e79fb467e743a097b449794830ad8a,
title = "Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas",
abstract = "Purpose: Delayed ferumoxytol enhancement on T1-weighted images appears visually similar to gadoteridol enhancement. The purpose of this study was to quantitatively compare ferumoxytol T1 enhancement to gadoteridol enhancement with an objective, semi-automated method. Methods: 206 sets of post-gadoteridol and 24 h post-ferumoxytol T1-weighted scans from 58 high grade glioma patients were analyzed (9 pre-chemoradiation, 111 < 90 days post-chemoradiation, 21 > 90 days post-chemoradiation, 65 post-bevacizumab scans). Enhancement volumes and signal intensities normalized to normal appearing tissue proximal to enhancement were calculated with a semi-automated method. Enhancement cube root volumes (D) and signal intensities (SI) were compared between the 2 contrast agents, and relative difference of D and SI were compared in different treatment groups with multivariate analysis. Within patient differences in D and SI before and after treatment with bevacizumab or steroid were assessed in 26 patients in each treatment group. Results: When compared to gadoteridol, ferumoxytol D was 13.83{\%} smaller and SI was 7.24{\%} lower (P < 0.0001). The relative differences in D and SI between the 2 contrast agents were not significantly different between treatment groups (P > 0.05). Relative difference in D and SI did not change significantly in response to bevacizumab (P = 0.5234 and P = 0.2442, respectively) or to steroid (P = 0.3774, P = 0.0741) in the within patient comparison. Conclusion: The correlation between the 2 contrast agents’ enhancement size and signal intensity and their similar behavior in response to therapy suggest that ferumoxytol can be used for revealing enhancement in high grade glioma patients. Magn Reson Med 80:224–230, 2018.",
keywords = "alternative contrast agent, delayed enhancement, ferumoxytol, gadoteridol, glioblastoma, USPIO",
author = "Andrea Horv{\'a}th and Varallyay, {Csanad G.} and Daniel Schwartz and Toth, {Gerda B.} and Netto, {Joao P.} and Ramon Barajas and P{\'e}ter V{\'a}rallyay and L{\'a}szl{\'o} Szidonya and Jenny Firkins and Emily Youngers and Rongwei Fu and Prakash Ambady and P. Bogner and Neuwelt, {Edward A.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1002/mrm.27028",
language = "English",
volume = "80",
pages = "224--230",
journal = "Magnetic Resonance in Medicine",
issn = "0740-3194",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas

AU - Horváth, Andrea

AU - Varallyay, Csanad G.

AU - Schwartz, Daniel

AU - Toth, Gerda B.

AU - Netto, Joao P.

AU - Barajas, Ramon

AU - Várallyay, Péter

AU - Szidonya, László

AU - Firkins, Jenny

AU - Youngers, Emily

AU - Fu, Rongwei

AU - Ambady, Prakash

AU - Bogner, P.

AU - Neuwelt, Edward A.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Purpose: Delayed ferumoxytol enhancement on T1-weighted images appears visually similar to gadoteridol enhancement. The purpose of this study was to quantitatively compare ferumoxytol T1 enhancement to gadoteridol enhancement with an objective, semi-automated method. Methods: 206 sets of post-gadoteridol and 24 h post-ferumoxytol T1-weighted scans from 58 high grade glioma patients were analyzed (9 pre-chemoradiation, 111 < 90 days post-chemoradiation, 21 > 90 days post-chemoradiation, 65 post-bevacizumab scans). Enhancement volumes and signal intensities normalized to normal appearing tissue proximal to enhancement were calculated with a semi-automated method. Enhancement cube root volumes (D) and signal intensities (SI) were compared between the 2 contrast agents, and relative difference of D and SI were compared in different treatment groups with multivariate analysis. Within patient differences in D and SI before and after treatment with bevacizumab or steroid were assessed in 26 patients in each treatment group. Results: When compared to gadoteridol, ferumoxytol D was 13.83% smaller and SI was 7.24% lower (P < 0.0001). The relative differences in D and SI between the 2 contrast agents were not significantly different between treatment groups (P > 0.05). Relative difference in D and SI did not change significantly in response to bevacizumab (P = 0.5234 and P = 0.2442, respectively) or to steroid (P = 0.3774, P = 0.0741) in the within patient comparison. Conclusion: The correlation between the 2 contrast agents’ enhancement size and signal intensity and their similar behavior in response to therapy suggest that ferumoxytol can be used for revealing enhancement in high grade glioma patients. Magn Reson Med 80:224–230, 2018.

AB - Purpose: Delayed ferumoxytol enhancement on T1-weighted images appears visually similar to gadoteridol enhancement. The purpose of this study was to quantitatively compare ferumoxytol T1 enhancement to gadoteridol enhancement with an objective, semi-automated method. Methods: 206 sets of post-gadoteridol and 24 h post-ferumoxytol T1-weighted scans from 58 high grade glioma patients were analyzed (9 pre-chemoradiation, 111 < 90 days post-chemoradiation, 21 > 90 days post-chemoradiation, 65 post-bevacizumab scans). Enhancement volumes and signal intensities normalized to normal appearing tissue proximal to enhancement were calculated with a semi-automated method. Enhancement cube root volumes (D) and signal intensities (SI) were compared between the 2 contrast agents, and relative difference of D and SI were compared in different treatment groups with multivariate analysis. Within patient differences in D and SI before and after treatment with bevacizumab or steroid were assessed in 26 patients in each treatment group. Results: When compared to gadoteridol, ferumoxytol D was 13.83% smaller and SI was 7.24% lower (P < 0.0001). The relative differences in D and SI between the 2 contrast agents were not significantly different between treatment groups (P > 0.05). Relative difference in D and SI did not change significantly in response to bevacizumab (P = 0.5234 and P = 0.2442, respectively) or to steroid (P = 0.3774, P = 0.0741) in the within patient comparison. Conclusion: The correlation between the 2 contrast agents’ enhancement size and signal intensity and their similar behavior in response to therapy suggest that ferumoxytol can be used for revealing enhancement in high grade glioma patients. Magn Reson Med 80:224–230, 2018.

KW - alternative contrast agent

KW - delayed enhancement

KW - ferumoxytol

KW - gadoteridol

KW - glioblastoma

KW - USPIO

UR - http://www.scopus.com/inward/record.url?scp=85037652951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037652951&partnerID=8YFLogxK

U2 - 10.1002/mrm.27028

DO - 10.1002/mrm.27028

M3 - Article

VL - 80

SP - 224

EP - 230

JO - Magnetic Resonance in Medicine

JF - Magnetic Resonance in Medicine

SN - 0740-3194

IS - 1

ER -